Fundacao Champalimaud
19
6
7
5
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 19 trials
100.0%
+13.5% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 5 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (19)
Single-Dose Image-Guided Radiotherapy With Urethral Sparing and DIL Boost for Intermediate-Risk Prostate Cancer (PROSINT II)
Role: lead
Single Dose Radiotherapy (SDRT) in Oligometatstasis Ablation
Role: lead
Long-term Follow-up of the TAM-01 Study and Pooled Analysis of Low-dose Tamoxifen Studies in Non-invasive or Microinvasive Breast Neoplasms
Role: collaborator
CARE-CRC: Microbiome Insights and Correlations for Risk and Outcomes in Colorectal Cancer
Role: collaborator
Comparing Decision on Aesthetics After Breast Cancer Locoregional Treatment.
Role: lead
An AI Platform Integrating Imaging Data and Models, Supporting Precision Care Through Prostate Cancer's Continuum
Role: collaborator
Resistance vs. Aerobic Training on Breast Cancer Patients Undergoing Neoadjuvant Treatment
Role: lead
In Vivo Cortical Excitability Modulation in Major Depressive Disorder
Role: lead
Improving Obsessive-compulsive Disorder Treatments: from Lesions to Neuromodulation Targets
Role: lead
Reinforcement Learning and Obsessive-compulsive Disorder: Exploring the Role of the Orbitofrontal Cortex
Role: lead
POSE - POs Surgery Endometrial Cancer
Role: lead
VIBE - Virtual Image Guided Brachytherapy Emulation for Locally Advanced Cervical Cancer (LACC)
Role: lead
Trial for Treatment of High Risk BC With Two Sequences of Neoadjuvant Chemotherapy With Pembrolizumab
Role: lead
Quantitative MRI and Outcomes of Liver Resection
Role: collaborator
Predicting Effective Adaptation to Breast Cancer to Help Women to BOUNCE Back
Role: collaborator
Single Dose Radiotherapy (SDRT) With or Without Adjuvant Systemic Therapy for Oligometastatic Prostate Cancer
Role: lead
Phase II Study of Ultra-high-dose Hypofractionated vs. Single-dose Image-Guided Radiotherapy for Prostate Cancer
Role: lead
Hypofractionated Image-Guided Radiotherapy (IGRT) With Organ Motion Mitigation and Urethral Sparing for Prostate Cancer
Role: lead
Stereotactic Hypofractionated Accelerated Radiotherapy Post-Prostatectomy
Role: lead
All 19 trials loaded